clinical trial · NCT07149857
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Janssen Research & Development, LLC·phase2·recruiting·n = 60
Multiple MyelomaCilta-celCyclophosphamideInduction therapyFludarabine
brief summary
The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.
started
Oct 3, 2025
primary completion
Apr 12, 2028
completion
Apr 6, 2029
last updated
Jun 5, 2026
official title
A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol